Mdxhealth Sa · NASDAQ:MDXH
Mdxhealth Sa — Investor Presentation (August 2026)
23 slides from Mdxhealth Sa's investor presentation, August 2026
Slide 1: Corporate Presentation
Corporate Presentation August 2026
Slide 2: Forward looking statement
Forward looking statement This presentation contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, mad
Slide 3: mdxhealth provides highly accurate and clinically actionable urologic solutions
Ticker: MDXH mdxhealth provides highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers © 2026 mdxhealth. All rights reserved. 3
Slide 4: mdxhealth fundamentals for growth
mdxhealth fundamentals for growth Fundamentals in place Levers for growth • Compelling and comprehensive menu in prostate • Expansion of mdxhealth clinical pathway for prostate cancer cancer (acquisition of Genomic Prostate Score & Exo mdx Prostate Test) • Robust clinical data • Expanding US commerc
Slide 5: Experienced leadership team
Experienced leadership team Track record of success Michael K. Ron John Joseph Kim McGarrity Kalfus Bellano Sollee Leroux Interim Chief Executive Officer Chief Financial Officer Chief Commercial Officer Executive Vice President Executive Vice President Corp. Dev. General Counsel Revenue Cycle Mgmt.
Slide 6: Our menu addresses a $4.8B U.S. market opportunity
Our menu addresses a $4.8B U.S. market opportunity(1-4) COMPREHENSIVE UROLOGY MENU $892M *In development $1.1B TOTAL $677M $4.8B $2.2B © 2026 mdxhealth. All rights reserved. 6
Slide 7: Commercial levers to drive growth
Commercial levers to drive growth One of the most compelling, comprehensive and accurate menus in urology AC QUIRE D SE PT EM BER 2 02 5 Standardized laboratory partner for urology group practice • One rep, One laboratory, One patient support program • ONE PARTNER in the diagnosis and treatment of p
Slide 8: Current challenges with diagnosing prostate cancer
Current challenges with diagnosing prostate cancer Prostate cancer Prostate cancer Prostate cancer screening diagnosis risk stratification ~3 elevated PSA results annually(1-2) ~500K men undergo biopsies annually(2) ~300K prostate cancers diagnosed annually(8) million of biopsies DO NOT of cancer-ne
Slide 9: Expanding menu in the prostate cancer diagnostic pathway
Expanding menu in the prostate cancer diagnostic pathway One of the most comprehensive menus in prostate cancer © 2026 mdxhealth. All rights reserved. 9
Slide 10: Non-invasive test for detection of clinically significant prostate cancer
a non-invasive (No DRE) test for the detection of clinically significant prostate cancer Non-invasive ExoDx informs if prostate biopsy is necessary, independent • NO DRE required • NO vigorous prostate massage of PSA and other standard of care information • Done “in-office” or with “At-Home Collecti
Slide 11: Improves diagnostic confidence of biopsy result
improves diagnostic confidence of biopsy result The only epigenetic test to identify men at risk Non-invasive for aggressive prostate cancer “Rule-out” test performed on previous biopsy tissue Accurate Validated False-negative biopsy 96% NPV (1) 96% Negative Predictive Over 55 published Value for ag
Slide 12: Guides treatment decisions for localized prostate cancer
guides treatment decisions for localized prostate cancer The test analyzes prostate cancer gene activity to predict Non-invasive disease aggressiveness and provide clinically meaningful test performed on previous biopsy tissue endpoints(1-23) Accurate Surveillance Predicts adverse pathology, distant
Slide 13: Prostate Cancer Pipeline
Prostate Cancer Pipeline Active surveillance monitoring (Localized prostate cancer) 1.5M Est. market size (men annually) Current Standard of Care Monitor mdx Patients under active surveillance are Monitor mdx will be a non-invasive alternative currently monitored by invasive and costly that risk-str
Slide 14: Selected Financial Data (from continuing operations)
Selected Financial Data (from continuing operations) Three months ended (unaudited) Six months ended (unaudited) In $’000 (except EPS) Jun 30, 2026 Jun 30, 2025 % Change Jun 30, 2026 Jun 30, 2025 % Change (*re-presented) (*re-presented) Total revenue $27,209 $23,394 +16% $51,106 $44,957 +14% Gross p
Slide 15: mdxhealth is well-positioned for sustainable growth and value creation
mdxhealth is well-positioned for sustainable growth and value creation Revenue growth Gross margin leverage • Multi-billion-dollar addressable market • Driving additional payer coverage for full menu opportunity fortified by acquisition of • Accretion of GPS and ExoDx tests GPS and ExoDx tests • 202
Slide 16: Thank you
Thank you INVESTOR RELATIONS GLOBAL OPERATIONS John Fraunces, Managing US Headquarters & Laboratory Director 15279 Alton Parkway, Ste 100 (917) 355-2395 Irvine, CA 92618 jfraunces@lifesciadvisors.com United States EU Headquarters CAP Business Center Rue d’Abhooz, 31 4040 Herstal, Belgium © 2026 mdxh
Slide 17: References
References Slide 6 – Our menu addresses a $4.9B U.S. market opportunity treatment decisions for localized prostate cancer cancer (PCa). PLoS One. 2017;12(10):e0185535. 1. MDxHealth management estimates 1. Brooks MA, et al. Validating the associate on of adverse pathology with distant 16. Kornberg Z,
Slide 18: Appendix
Appendix mdxhealth
Slide 19: Exo mdx robust clinical evidence
Exo mdx robust clinical evidence 11 published studies on ExoDx Analytical Clinical Clinical Health validity validity utility economics PIVOTAL CLINICAL STUDIES McKiernan et al., Clinically validated for a 91% NPV JAMA Oncology, 2016 Prospective Utility Study McKiernan et al., European Urology 2018 T
Slide 20: Confirm mdx robust clinical evidence
Confirm mdx robust clinical evidence Over 55 published studies on genes and technology Analytical Clinical Clinical Health validity validity utility economics PIVOTAL CLINICAL STUDIES Van Neste et al., Analytical validation BMC Urology 2013 Partin et al., Validation of high NPV Journal of Urology 20
Slide 21: GPS robust clinical evidence
GPS robust clinical evidence Over 20 published clinical validation and utility studies Analytical Clinical Clinical Health validity validity utility economics PIVOTAL CLINICAL STUDIES Analytical validation Knezevic et al., 2013 Clinically validated as an Klein et al., 2014, Cullen et al., 2015, Eede
Slide 22: ExoDx, Confirm mdx and GPS technology
ExoDx, Confirm mdx and GPS technology The most comprehensive menu in prostate cancer ExoDx(1) Confirm mdx(2) GPS(3) Specimen Urine Prostate tissue Localized PCa tissue Science RNA Exosomes DNA Methylation Specific PCR assay Multi gene expression RT-PCR Assay AZGP1, FAM13C, KLK2, SRD5A2, FLNC Biomark
Slide 23: Unaudited reconciliation of IFRS to non-IFRS financial measures
Unaudited reconciliation of IFRS to non-IFRS financial measures Non-IFRS disclosure In addition to the Company’s financial results determined in accordance with IFRS, the Company provides adjusted EBITDA and adjusted EBITDA margin, non-IFRS measures that the Company determines to be useful in evalua